Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Yan Cheng, MD, PhD
Chengdu Kanghong Biotechnology Co.,Ltd.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
154 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Kanghong Investigative Site
Plovdiv, Bulgaria
- Kanghong Investigative Site
Sofia, Bulgaria
- Kanghong Investigative Site
Sofia, Bulgaria
- Kanghong Investigative Site
Varna, Bulgaria
- Kanghong Investigative Site
Beijing, Beijing Municipality, China
- Kanghong Investigative Site
Shanghai, Shanghai Municipality, China
- Kanghong Investigative Site
Shanghai, Shanghai Municipality, China
- Kanghong Investigative Site
Tianjin, Tianjin Municipality, China
- Kanghong Investigative Site
Brno, Czechia
- Kanghong Investigative Site
Prague, Czechia
- Kanghong Investigative Site
Prague, Czechia
- Kanghong Investigative Site
Prague, Czechia
- Kanghong Investigative Site
Prague, Czechia
- Kanghong Investigative Site
Aalborg, Denmark
- Kanghong Investigative Site
Aarhus N, Denmark
- Kanghong Investigative Site
Glostrup Municipality, Denmark
- Kanghong Investigative Site
Roskilde, Denmark
- Kanghong Investigative Site
Sønderborg, Denmark
- Kanghong Investigative Site
Bordeaux, France
- Kanghong Investigative Site
Créteil, France
- Kanghong Investigative Site
Dijon, France
- Kanghong Investigative Site
Marseille, France
- Kanghong Investigative Site
Paris, France
- Kanghong Investigative Site
Paris, France
- Kanghong Investigative Site
Paris, France
- Kanghong Investigative Site
Paris, France
- Kanghong Investigative Site
Poitiers, France
- Kanghong Investigative Site
Saint-Cyr-sur-Loire, France
- Kanghong Investigative Site
Strasbourg, France
- Kanghong Investigative Site
Pécs, Baranya, Hungary
- Kanghong Investigative Site
Szeged, Csongrád megye, Hungary
- Kanghong Investigative Site
Debrecen, Hajdú-Bihar, Hungary
- Kanghong Investigative Site
Budapest, Pest County, Hungary
- Kanghong Investigative Site
Budapest, Pest County, Hungary
- Kanghong Investigative Site
Budapest, Pest County, Hungary
- Kanghong Investigative Site
Budapest, Pest County, Hungary
- Kanghong Investigative Site
Budapest, Pest County, Hungary
- Kanghong Investigative Site
Budapest, Pest County, Hungary
- Kanghong Investigative Site
Zalaegerszeg, Zala County, Hungary
- Kanghong Investigative Site
Ashkelon, Ha'Darom, Israel
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Dec 2018
- Primary completion
- 10 Sept 2020
- Completion
- 19 May 2021
- Last update posted
- 23 Jun 2021
- Registered enrollment
- 1,157
- Registry id
- NCT03630952
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.